Insights

Innovative Delivery Platforms SmartCella's proprietary Extroducer® device offers advanced targeted delivery solutions for hard-to-reach organs and tumors, presenting opportunities to collaborate with biotech firms seeking novel therapeutic delivery methods.

Strategic Industry Partnerships Recent collaborations with Oloker Therapeutics and Catalent demonstrate SmartCella’s active engagement in expanding its technological reach and manufacturing capabilities, offering potential for joint development and licensing opportunities.

Funding and Growth With recent investments totaling over 54 million USD and a focus on accelerating therapy development, there is a demand for supporting technologies in manufacturing, R&D, and clinical research to meet rapid growth plans.

Biotech Expertise Backed by prominent research from Karolinska Institutet and led by experienced executives, SmartCella is positioned at the forefront of regenerative medicine and targeted therapies, creating opportunities in advanced cell therapy and personalized medicine markets.

Focus on Cell Therapies The company's focus on developing iPSC-based therapies and regenerative medicines suggests potential sales opportunities in bioprocessing equipment, cell culture technologies, and quality assurance solutions tailored for advanced cell manufacturing.

Similar companies to SmartCella Holding AB

SmartCella Holding AB Tech Stack

SmartCella Holding AB uses 8 technology products and services including WordPress Super Cache, ISO 13485, cdnjs, and more. Explore SmartCella Holding AB's tech stack below.

  • WordPress Super Cache
    Caching
  • ISO 13485
    Certificates
  • cdnjs
    Content Delivery Network
  • WordPress
    Content Management System
  • LoopiaDNS
    Domain Name Services
  • Microsoft Outlook
    Email
  • Punycode
    Font Scripts
  • Highcharts
    Javascript Graphics

Media & News

SmartCella Holding AB's Email Address Formats

SmartCella Holding AB uses at least 2 format(s):
SmartCella Holding AB Email FormatsExamplePercentage
First.Last@procella.seJohn.Doe@procella.se
98%
First.Middle.Last@procella.seJohn.Michael.Doe@procella.se
2%
First.Last@smartcella.comJohn.Doe@smartcella.com
100%

Frequently Asked Questions

What is SmartCella Holding AB's official website and social media links?

Minus sign iconPlus sign icon
SmartCella Holding AB's official website is smartcella.com and has social profiles on LinkedInCrunchbase.

What is SmartCella Holding AB's SIC code NAICS code?

Minus sign iconPlus sign icon
SmartCella Holding AB's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does SmartCella Holding AB have currently?

Minus sign iconPlus sign icon
As of July 2026, SmartCella Holding AB has approximately 64 employees across 1 continents, including Europe. Key team members include Coo: J. R.Chief Commercial Officer (cco): S. O.Chief Financial Officer: O. S.. Explore SmartCella Holding AB's employee directory with LeadIQ.

What industry does SmartCella Holding AB belong to?

Minus sign iconPlus sign icon
SmartCella Holding AB operates in the Biotechnology Research industry.

What technology does SmartCella Holding AB use?

Minus sign iconPlus sign icon
SmartCella Holding AB's tech stack includes WordPress Super CacheISO 13485cdnjsWordPressLoopiaDNSMicrosoft OutlookPunycodeHighcharts.

What is SmartCella Holding AB's email format?

Minus sign iconPlus sign icon
SmartCella Holding AB's email format typically follows the pattern of First.Last@procella.se. Find more SmartCella Holding AB email formats with LeadIQ.

How much funding has SmartCella Holding AB raised to date?

Minus sign iconPlus sign icon
As of July 2026, SmartCella Holding AB has raised $54M in funding. for $54M.

When was SmartCella Holding AB founded?

Minus sign iconPlus sign icon
SmartCella Holding AB was founded in 2014.
SmartCella Holding AB logo

SmartCella Holding AB

Biotechnology ResearchStockholm, Sweden51-200 Employees

SmartCella Holding AB is a biotechnology research company based in Tullinge, in the Stockholm region of Sweden. Founded in 2014, it builds on science from Karolinska Institutet to develop therapies derived from living systems and pursue targeted approaches for difficult-to-treat diseases through delivery solutions and advanced therapy development. The company has two operating segments, Targeted Delivery and Regenerative Medicines, and has developed the Extroducer, an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors, alongside development and manufacturing of cell therapies. Its focus is on researchers and biopharma developers seeking novel delivery and cell-therapy platforms. In May 2026, SmartCella announced a licensing agreement with Oloker Therapeutics to extend Extroducer technology for targeted delivery.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $54M

    SmartCella Holding AB has raised a total of $54M of funding over 2 rounds. in the amount of $54M.

  • $1M

    SmartCella Holding AB's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $54M

    SmartCella Holding AB has raised a total of $54M of funding over 2 rounds. in the amount of $54M.

  • $1M

    SmartCella Holding AB's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.